Prognosis analysis in the samples without EGFR amplification demonstrated that breast cancer patients with high expression of SEC61G had significantly worse overall survival (OS) and disease-free survival (DFS) than those patients with low expression of SEC61G in TCGA BRCA cohort (Fig. 1C, D). Here, EGFR is linked to breast carcinoma.